MiR-613 induces cell cycle arrest by targeting CDK4 in non-small cell lung cancer

Cellular Oncology

Volumn 39, Issue 2, 2016, Pages 139-147

  Li, Duo ^a   Li, Dong Qiong ^a   Liu, Dan ^a   Tang, Xiao Jun ^a  

^a THE AFFILIATED HOSPITAL OF SOUTHWEST MEDICAL UNIVERSITY   (China)

Author keywords

CDK4; Cell cycle; Lung cancer; miR 613

Indexed keywords

CYCLIN DEPENDENT KINASE 4; MESSENGER RNA; MICRORNA; MICRORNA 163; UNCLASSIFIED DRUG; CDK4 PROTEIN, HUMAN; MIRN613 MICRORNA, HUMAN;

3' UNTRANSLATED REGION; ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER GRADING; CANCER INHIBITION; CANCER STAGING; CARCINOGENICITY; CELL CYCLE ARREST; CELL VIABILITY; COLONY FORMATION; COLONY FORMING UNIT; COMPUTER MODEL; CONTROLLED STUDY; DOWN REGULATION; FEMALE; FLOW CYTOMETRY; GENE EXPRESSION; HEK293 CELL LINE; HUMAN; HUMAN CELL; IN VITRO STUDY; MALE; MOUSE; NON SMALL CELL LUNG CANCER; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR XENOGRAFT; UPREGULATION; WESTERN BLOTTING; AGED; ANIMAL; CELL CYCLE CHECKPOINT; CELL PROLIFERATION; GENE SILENCING; GENETICS; LUNG TUMOR; METABOLISM; MIDDLE AGED; NUDE MOUSE; PATHOLOGY;

ADULT; AGED; ANIMALS; BASE SEQUENCE; CARCINOMA, NON-SMALL-CELL LUNG; CELL CYCLE CHECKPOINTS; CELL PROLIFERATION; CYCLIN-DEPENDENT KINASE 4; DOWN-REGULATION; FEMALE; GENE KNOCKDOWN TECHNIQUES; HUMANS; LUNG NEOPLASMS; MALE; MICE, NUDE; MICRORNAS; MIDDLE AGED;

EID: 84953396873     PISSN: 22113428     EISSN: 22113436     Source Type: Journal    
DOI: 10.1007/s13402-015-0262-4     Document Type: Article

References (36)

1. H. Uramoto, F. Tanaka, Recurrence after surgery in patients with NSCLC. Transl. Lung Cancer Res. 3, 242–249 (2014)
2. A. Koren, E. Sodja, M. Rijavec, M. Jez, V. Kovac, P. Korosec, T. Cufer, Prognostic value of cytokeratin-7 mRNA expression in peripheral whole blood of advanced lung adenocarcinoma patients. Cell. Oncol. 38, 387–395 (2015)
3. C. Zeng, W. Fan, X. Zhang, RRM1 expression is associated with the outcome of gemcitabine-based treatment of non-small cell lung cancer patients–a short report. Cell. Oncol. 38, 319–325 (2015)
4. Z. Birsu Cincin, M. Unlu, B. Kiran, E. Sinem Bireller, Y. Baran, B. Cakmakoglu, Anti-proliferative, apoptotic and signal transduction effects of hesperidin in non-small cell lung cancer cells. Cell. Oncol. 38, 195–204 (2015)
5. Q. Wu, Y. F. Chen, J. Fu, Q. H. You, S. M. Wang, X. Huang, X. J. Feng, S. H. Zhang, Short hairpin RNA-mediated down-regulation of CENP-A attenuates the aggressive phenotype of lung adenocarcinoma cells. Cell. Oncol. 37, 399–407 (2014)
6. F. De Marinis, E. Bria, P. Baas, M. Tiseo, A. Camerini, A. G. Favaretto, C. Gridelli, Treatment of unfit patients with advanced non-small-cell lung cancer: definition criteria according an expert panel. Clin. Lung Cancer. 16, 399–405 (2015)
7. S. N. Bichev, D. M. Marinova, Y. G. Slavova, A. S. Savov, Epidermal growth factor receptor mutations in East European non-small cell lung cancer patients. Cell. Oncol. 38, 145–153 (2015)
8. E. Prodromaki, A. Korpetinou, E. Giannopoulou, E. Vlotinou, M. Chatziathanasiadou, N. I. Papachristou, C. D. Scopa, H. Papadaki, H. P. Kalofonos, D. J. Papachristou, Expression of the microRNA regulators Drosha, Dicer and Ago2 in non-small cell lung carcinomas. Cell. Oncol. 38, 307–317(2015)
9. L. C. Villaruz, M. A. Socinski, The role of anti-angiogenesis in non-small-cell lung cancer: an update. Curr. Oncol. Rep. 17, 26 (2015)
10. V. Del Vescovo, M. Grasso, M. Barbareschi, M. A. Denti, MicroRNAs as lung cancer biomarkers. World J. Clin. Oncol. 5, 604–620 (2014)
11. D. P. Bartel, MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 116, 281–297 (2004)
12. R. Schickel, B. Boyerinas, S. M. Park, M. E. Peter, MicroRNAs: key players in the immune system, differentiation, tumorigenesis and cell death. Oncogene 27, 5959–5974 (2008)
13. K. U. Tufekci, R. L. Meuwissen, S. Genc, The role of microRNAs in biological processes. Meth. Mol. Biol. 1107, 15–31 (2014)
14. O. Fortunato, M. Boeri, C. Verri, M. Moro M, G. Sozzi, Therapeutic use of microRNAs in lung cancer. Biomed. Res. Int. 2014, 756975(2014)
15. J. Silber, C. D. James, J. G. Hodgson, microRNAs in Gliomas: small Regulators of a big Problem. Neruomol. Med. 11, 208–222 (2009)
16. A. L. Zimmerman, S. Wu, MicroRNAs, cancer and cancer stem cells. Cancer Lett. 300, 10–19 (2011)
17. J. Li, Y. Wang, Y. Song, Z. Fu, W. Yu, miR-27a regulates cisplatin resistance and metastasis by targeting RKIP in human lung adenocarcinoma cells. Mol. Cancer. 13, 193(2014)
18. J. Li, Q. Wang, R. Wen, J. Liang, X. Zhong, W. Yang, D. Su, J. Tang, MiR-138 inhibits cell proliferation and reverses epithelial-mesenchymal transition in non-small cell lung cancer cells by targeting GIT1 and SEMA4C. J. Cell. Mol. Med. 2015. doi:10.1111/jcmm.12666
19. Y. S. Wang, Y. H. Wang, H. P. Xia, S. W. Zhou, G. Schmid-Bindert, C. C. Zhou, MicroRNA-214 regulates the acquired resistance to gefitinib via the PTEN/AKT pathway in EGFR-mutant cell lines. Asian Pac. J. Cancer Prev. 13, 255–260 (2012)
20. Y. J. Zhang, F. Xu, Y. J. Zhang, H. B. Li, J. C. Han, L. Li, miR-206 inhibits non small cell lung cancer cell proliferation and invasion by targeting SOX9. Int. J. Clin Exp. Med. 8, 9107–9113 (2015)
21. M. Wang, Q. Zhang, J. Wang, Y. Zhai, MicroRNA-498 is downregulated in non-small cell lung cancer and correlates with tumor progression. J. Cancer Res. Ther. 11, c107–c111 (2015)
22. D. Cortinovis, V. Monica, F. Pietrantonio, G. L. Ceresoli, C. M. La Spina, L. Wannesson, MicroRNAs in non-small cell lung cancer: current status and future therapeutic promises. Curr. Pharm. 20, 3982–3990 (2014)
23. I. Vannini, F. Fanini, M. Fabbri, MicroRNAs as lung cancer biomarkers and key players in lung carcinogenesis. Clin. Biochem. 46, 918–925 (2013)
24. M. Boeri, U. Pastorino, G. Sozzi, Role of microRNAs in lung cancer: microRNA signatures in cancer prognosis. Cancer J. 18, 268–274 (2012)
25. R. Zhao, J. Feng, G. He, miR-613 regulates cholesterol efflux by targeting LXRα and ABCA1 in PPARγ activated THP-1 macrophages. Biochem. Biophys. Res. Commun. 448, 329–334 (2014)
26. D. Zhong, Y. Zhang, Y. J. Zeng, M. Gao, G. Z. Wu, C. J. Hu, G. Huang, F. T. He, MicroRNA-613 represses lipogenesis in HepG2 cells by downregulating LXRα. Lipids Health Dis. 12(32) (2013)
27. Z. Ou, T. Wada, R. Gramignoli, S. Li, S. C. Strom, M. Huang, W. Xie, MicroRNA hsa-miR-613 targets the human LXRα gene and mediates a feedback loop of LXRα autoregulation. Mol. Endocrinol. 25, 584–596 (2011)
28. Anton R, Chatterjee SS, Simundza J, Cowin P, Dasgupta R. A systematic screen for micro-RNAs regulating the canonical Wnt pathway. PLoS One. 6, e26257(2011)
29. R. W. Georgantas 3rd, K. Streicher, X. Luo, L. Greenlees, W. Zhu, Z. Liu, P. Brohawn, C. Morehouse, B. W. Higgs, L. Richman, B. Jallal, Y. Yao, K. Ranade, MicroRNA-206 induces G1 arrest in melanoma by inhibition of CDK4 and cyclin D. Pigment Cell Melanoma Res. 27, 275–286 (2014)
30. G. Liu, Y. Sun, P. Ji, X. Li, D. Cogdell, D. Yang, B. C. Parker Kerrigan, I. Shmulevich, K. Chen, A. K. Sood, F. Xue, W. Zhang, MiR-506 suppresses proliferation and induces senescence by directly targeting the CDK4/6-FOXM1 axis in ovarian cancer. J. Pathol. 233, 308–318 (2014)
31. S. Qiu, D. Huang, D. Yin, F. Li, X. Li, H. F. Kung, Y. Peng, Suppression of tumorigenicity by microRNA-138 through inhibition of EZH2-CDK4/6-pRb-E2F1 signal loop in glioblastoma multiforme. Biochim. Biophys. Acta 1832, 1697–1707 (2013)
32. T. Feng, D. Xu, C. Tu, W. Li, Y. Ning, J. Ding, S. Wang, L. Yuan, N. Xu, K. Qian, Y. Wang, C. Qi, miR-124 inhibits cell proliferation in breast cancer through downregulation of CDK4. Tumour Biol. 36, 5987–5997 (2015)
33. X. Deng, L. Ma, M. Wu, G. Zhang, C. Jin, Y. Guo, R. Liu, miR-124 radiosensitizes human glioma cells by targeting CDK4. J. Neuro-Oncol. 114, 263–274 (2013)
34. B. Du, Z. Wang, X. Zhang, S. Feng, G. Wang, J. He, B. Zhang, MicroRNA-545 suppresses cell proliferation by targeting cyclin D1 and CDK4 in lung cancer cells. PLoS One 9, e88022 (2014)
35. S. L. Lin, D. C. Chang, S. Y. Ying, D. Leu, D. T. Wu, MicroRNA miR-302 inhibits the tumorigenecity of human pluripotent stem cells by coordinate suppression of the CDK2 and CDK4/6 cell cycle pathways. Cancer Res. 70, 9473–9482 (2010)
36. M. Grillo, M. J. Bott, N. Khandke, J. P. McGinnis, M. Miranda, M. Meyyappan, E. C. Rosfjord, S. K. Rabindran, Validation of cyclin D1/CDK4 as an anticancer drug target in MCF-7 breast cancer cells: effect of regulated overexpression of cyclin D1 and siRNA-mediated inhibition of endogenous cyclin D1 and CDK4 expression. Breast Cancer Res. Treat. 95, 185–194 (2006)